PODD - Earnings call transcript Q2 2019

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good day, ladies and gentlemen and welcome to the Second Quarter 2019 Insulet Corporation Earnings Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session and instructions will follow at that time [Operator Instructions].

As a reminder, this conference call is being recorded.

I would now like to introduce your host for today's conference, Mrs. Investor Corporate President, Vice Gordon, Relations Communications. and Deborah please go ahead. Ma'am,

Deborah Gordon

thank Lauren. XXXX joining Good you, you Earnings afternoon Quarter Thank Second and for Insulet us Call. for

and Investor President me Financial Chief our replay will Chief Joining website Shacey call The Executive Petrovic, this archived are Executive President full our Relation today Officer. available results and Officer; be Wayde of XXXX our second press quarter also website. our release and issued of and is quarter section after year McMillan, Vice and and market in guidance close the today on discussing XXXX third

include year-over-year SEC. if GAAP Before of and addition during quarter statements I a the expectations earnings forward by like looking the update the uncertainties and even actual results those that that known materially be in you forward Insulet in this or basis. our we results will risks unless uncertainties of in we involve with begin, may may from and filings commentary Safe on implied second call our be these the cause to Company's dollar change financial statements and such note no referenced materially. results inform be any future regarding course forward-looking such limitations obligation release to by risks would different Such unknown that made statements. statements assume to stated, and to statement future Also, certain and otherwise inherent actual Please Harbor in all percentage looking changes

turn And to over I'll Shacey. with that, the call

Shacey Petrovic

everyone. afternoon good and Deb, Thanks,

position to profitable strategic made we operational throughout and we to and strength and the working our exciting the imperatives are sustainable midpoint We XXXX from great another progress financial second The extremely for for one important long-term growth. a our XXXX was Insulet entered XXXX our as year. of of solidify cross after on foundation quarter and have pleased of

operational driving first team's to Second, disciplined Insulet strategic third: achieved organization. execution revenue our quarter accelerated global market on access; our focused innovation throughout the imperatives; strengthening focus imperatives expanding ensuring business; Thanks across remain growth. of and great We excellence fourth our our these and and another our footprint

we are XXXX As year guidance. a our raising full result,

the is Our people and These estimate the X the our Today, opportunity trends Type for large, XX business. use dependent it growing. market provide is living almost countries manage both to under-penetrated. with diabetes million growing Type market are it currently is the and addressable serve of disease and of we strong incidence diabetes. tailwinds we Globally X insulin in technology our

We innovation have a we into ability new to market. drive such our long-term addressable product expect number both and our us will growth financial drivers long-term and in confidence global These continued our make and near as XXXX our will that increase catalyst growth market growth. and expansion which targets penetration of our

our to the call will call, today's second On Wade, turn outlook. who an on quarter additional provide over financial review I I our will imperatives. to then results from will the share on and progress our quarter XXXX the detail financial and highlights update strategic share

growth the This will was delivered a benefit including diabetes we revenue by by revenue for quarter, in of in the the exceeding open call representing global million strategy million our Europe. $XX increase year-over-year. In We one-time XX% our then questions. go-direct $XXX second at guidance end our the driven in high XX% and

of a said to significant in last making, QX. the initiatives number we we had quarter in after As coming fruition years

Our achievement. team across of extremely over executed in well resulting all our them,

the laser lives on living core improving initiatives our remain focused strategic We with continue to make people progress of across and diabetes.

patients recommend of Omnipod would DASH since and satisfied DASH access, DASH, next of launch platform the to DASH. survey get superb of first generation internal full were innovation on with commercial approximately our DASH feedback has had of users last of our a quarter's with and use XX% friend. market we very started an and been thousands Starting Customer have ease

DASH on to a app was vision PDM customers interface locked clear There user designed towards personal intuitive PODs is advanced how for phone. as their from being a how down smartphones appreciation new has and The Insulet the mobile is Android their of customer able our control

of more customers with expanded approximately XX% majority is than coverage have our for and access US was growing channel. DASH shipped Omnipod DASH all By our reimbursemen. work of third end commensurate the of DASH a covered Also to pharmacy received new this utilization DASH establish vast quarter, of QX, and the to we through lives. the

to the to several working physicians, channel access We experience their best-in-class advantages payers. continue in because a and this provides and pharmacy expand customer for are patients

PODs ended this with base on total to through from XX% channel, focus pharmacy is XX% Our XX% our XXXX of QX XX% channel their US customer results. delivering the previously. We of up receiving to

low for charge use it choose has response There because industry have and to its The barriers Omnipod. to remove Omnipod technology stakeholders of lock with DASH four now pay-as-you-go and changing insulin in and is model. not is should patients innovative recommending game of and no enthusiastic business no pump efforts year who Omnipod the feel and our upfront only commitment, in Pod more therapy. pathway. periods period. lock-in DASHis the upfront customer can patients treatment afforded new of physicians been adoption earlier drive these confident We cost can simplicity, Because low more for or otherwise cost might believe

on of highs new indications time risk paying patient US early DASH our cost off. member have that And patient and demand the strategy are we There at are and is . reduced all payer attrition. starts the side, record

otherwise pump a they not users physicians We they and multiple us now would that patients have established recommended told market X for DASH relatively for short and considering of daily in period access have significant are have time injection Type therapy.

be use to and technology of showing discretion dependent people appealing valuable its Type and a with diabetes. to Thanks for X living particularly insulin simplicity, DASH is ease

benefits and understand segment and DASH grow. to continue patients is have this We X to to customer that expect and ensure messaging unique for we launched educational type physicians users initiatives

to the to beneficiaries. access broadening Medicare and of Omnipod XX% Medicaid this second greater to end of By for secure we we DASH, coverage coverage successfully continue than all all addition one-third expanded In QX to over up we Medicare XX% quarter, lives of at end half lives for over from and at Medicaid approximately QX. the with just up from last of quarter ended of expanded the end coverage

terms treatment be pathway powerful up launches the year. next Omnipod advantageous Horizon moving the will Omnipod building our when and The in business for access in are all foundation of leveraging we model pharmacy it building

to on remain of making We are great clinical with Xth quarter and start product the development year. in pivotal Horizon's this progress and track

Omnipod Because Horizon on-body, control. will from system users bathing Horizon's closed-loop itself, glycemic in designed time pod exercise. system the means for that a Horizon differentiator from tube personal in having daily with is provide is improve waterproof range in like Omnipod CGM, to an is more in loop smartphone This resides both crucial more the always activities disconnect on traditional without control time will or them communication pod that the with and closed loop algorithm hybrid and benefit architecture direct to pump. keeps It

which to participants therapy compelling X control American on significantly shown was children, Omnipod in ages to time presented their the better study data in range At which X compared through glycemic significantly June's, glucose usual spend were Conference hyperglycemia, less pump Horizon spend therapy and included to more and Annual sensor-augmented Diabetes have time target in MDI overnight

can the many target young proper the overnight period. During control of the the time glycemic of of maintaining in have. study, impact it during the range the given for maintained time This remarkable for children was and challenges of indicator this glucose powerful is early XX% overall a is and control XX% the Horizon

use are well and for of aware off label and or support and to studied of safe loop users. population want of algorithm system make We this that cannot condone is a the it, we sure we effective while broad growing

DIY on loop We and iOS-based commercially communities get by the and Tidepool automated Omnipod. FDA algorithm insulin are with the supported in system delivery marketplace working the cleared to

yet a patient to choice provides internal convenience will and driven This additive our we store which to passionate Management. the system, of is iPhone, to support are This and program Insulin through Horizon from and opportunity be app Omnipod accessed level another the pleased user's the community. have to DIY

the access, footprint position In and our addition market product where is our outside and States strengthening the leadership United on we to addressable continue innovation of and growing. to large focus solidifying global market

existing markets. the with through are been Europe result just Our has our we place insights a and in direct engagement year penetration market over as increasing our in one operations stakeholders, of have gained we for direct in

patients Some successes are are France majority for all time Omnipod examples of ever. starting now of therapy the clinics Kingdom regularly the today XX United choosing And team the first Omnipod. where pump prescribing where include the approximately new

We Omnipod also tenders that European are our broadening awarded to have throughout access new been markets. existing

see of We additional growth markets the to for including value expand XXXX. continued existing opportunities DASH in into to our where drive in strategic geographies to are well innovation long-term, positioned drive growth new launch we and and

on global to expect focus to during significant in begin opportunities existing the XXXX. We our our and XXXX in will expand footprint markets

US production And the in manufacturing. US began we our finally, highly new first to manufacturing In in automated excellence Massachusetts. operational line quarter, turning second our on

to gross further headwind rapid new we production. to and growth, transfer year manufacturing gross of install efficiencies investment redundancy landed margin margin, later technology and innovation manufacturing. into product the the of plan on cost realize this and lower to long XXXX. is expect efficiency, second in While a remain this given expansion term supports our ramp US our significant provides over supports our effective begin line This manufacturing production efficient and We

made market operational another growth. throughout our team's ensuring Insulet. including and the significant our great delivered on focus execution excellence innovation, quarter we of summary, dollar progress global revenue increasing strategic access, and record imperatives footprint This In strengthening

consecutive QX fact Insulet's positive our greater and income XX% In of income. than fourth and growth net quarter fourth quarter operating marked of revenue consecutive

will I over that to the call With now Wayde. turn

Wayde McMillan

Shacey. you, Thank

the beginning we our In we our solutions. of while carrying accelerating noted to scale continue people had quarter million remaining representing we which realizing end growth focused second execute imperatives, profitably $XX of are revenue mission our the revenue the on results $XXX.X we improving quarter the call, XXXX, quarter was by million high each of of as or of through We Shacey As out $XX.X had strong improved across range. growth of another of diabetes as strategic above at our guidance the with XX% innovative million lives financial

while new was range. This mix guidance the $XX.X our DASH base third of channel managing resulted the end row line the the This growth market launch Omnipod acceleration $X Product, our from primarily access and in the in of million the benefit pharmacy of above to revenue pharmacy XX% and US of to was a US in By the a to through product. and customer expanded by transition driven million the grew shift accelerating the growth the of model. premium from the pay-as-you-go Omnipod high which quarter launch

we we high In are exceeded million within DASH of primarily European due growing the our by model for successfully able and our to a markets the including model the launch guidance million benefit our direct exceeding because the range to of high guidance of PDM. revenue the grew Omnipod demand shift quarter, International business end $X Omnipod $XX.X Europe. end XXX% and through existing no-charge business range in our to navigate

the QX quarter converting in reminder, Omnipod a from a price XX% our of the direct reflects year-over-year uplift revenue to model. incremental business final European growth As international in

and above the European impact had we year. comparison negative $XX.X to buyback a our our when revenue prior expectations. was from delivery former an million, million inventory of in the reduction X% we Additionally, QX the easier from transition due Drug in distributor $X

to delivered points margin, second XXX quarter down XX.X% and in points we gross sequentially. Turning XX basis year-over-year basis the

As we QX impact sequential partial US earnings given call, manufacturing our in in quarter communicated on the decline the gross a margin we of to guided last quarter's ramp.

and through inefficiencies a incur period we the costs production, working increase as we normal start-up including costs As plant startup. as training well certain new of

the We continue to first and established and for capabilities expect for Insulet. add we these time manufacturing some as future facility headwinds manufacturing lines

of XX.X% with quarter an million than accelerating line year representing X.X% the operating representing We to increased revenue, income were in R&D production. of investments year. of increase of and $X.X a in expectations expenses period of full ended X% with $X.X income net just of revenue. as prior million less revenue US manufacturing expenses year-over-year and Operating included innovation of XX% over result prior starting XX.X% and

We the $XXX million the flow. year, last positive quarter to and ended cash of and at the we and with generated the quarter $XXX first million of at end $XXX investments in cash compared end operational million

as and our We continue to expenditures capital supply cash invest in operations. use chain for we planned US manufacturing

In are confident the revenue of summary, us with are of this we will quarter pleased investment growth, second and carry profitability through XXXX. the in half acceleration of and we level the momentum

long over We are well revenue continued growth term. positioned the and for profitability

Next, an update on our guidance. XXXX

million, our revenue our $XXX XX% up through of in expectation to million. By at growth year the the low of the our of to XX% the previous This and now result access wins million from the $XXX half end. $XX customer raising of million are guidance US momentum new our to reflects of starts. of to $XXX the million growth of in guidance million representing record by a Omnipod first strong representing $XXX XXXX, the and patient range for raising We our are market million As base growth line, to we confidence $XX total million $XXX rest range expect year end high given our and XX% expectations of revenue strong product at anticipated $XXX XX%. of to full XXXX we

We're is growth. recently and fueling product our off launched DASH with start to Omnipod our this strong already a great

benefit premium. neutralize million We no new expect existing resulting DASH to to us due slight million continue year, a of PDM the users during at $X our the the DASH-PDM and to pods mix full of and a expect headwind year purchasing $X to cost from for

expected of expectation from of the For and this we up are of in $XXX of a from buyback revenue our base year-over-year quarter. range million international our growth to XXXX resulting our inventory past million million, $XXX to the $XXX to than Omnipod, raising representing growth revenue $XXX to XX% million half the includes previous the customer this first year, growth XX% higher QX higher

continue the low capitalize our growth year direct presence. our expect line. international normalized growth in to European markets our to XX% product position existing We to the We're on for a in mid-teens our in for strong given great

expectation million raising our $XX revenue a $XX of drug million This $XX a million are X% Lastly improved for previous we of delivery, to our range $XX to to million. to X%. decline of has representing from

of of revenue XXXX, $XXX deliver third the million $XXX For to XX%. of to quarter XX% we expect million to in the growth representing range

Omnipod growth includes million of million This US $XX revenue $XXX to representing XX%. of XX% to

international of $XX growth XX%. expect $XX also to XX% Omnipod representing revenue to of million We million

expect Lastly, we XX% of to million of million $XX delivery a representing decline drug XX%. revenue $XX to

of the manufacturing. For benefit supply headwinds relatively year benefit reaffirming and expect establishing consistent This pay-as-you-go gross mix the offset the our prior full rest are by with in our model, direct we ramp be going XXXX the of improvements P&L, from the reflects and we that margin of to and operating the year. of continued Europe chain US

to to and US expect remainder lower first for half half during of the ramp, the the the XXXX. impact further year than margin into of the second the due be the of gross year We manufacturing

to QX XXXX be expect of and up also the within the quarter the costs given lowest We timing ramp year. period in

As operational most and competency core aware, around global developing excellence best-in-class we of are within are a manufacturing. you Insulet

with co-located Manufacturing is our to product scale also to manufacturing implement It this to now a complexity at of replicate. innovation own is our operations, advantage significant and have a teams. difficult

through our production continue our process remain we customer planned growing ramp scale levels to confident We the to are managing and serve will early to base.

our operating XX%. prior up XXXX to of expectations XX% from expect increase now We expenses approximately

year contributions cost range opportunity expectations variable term. percentage and capital expect for expect increase XXXX still we the single-digit drive associated in result change estimate be mid margin a expansion costs our consistent to US continue reductions corresponding the investment of Our in we relatively long innovation. increase redundancy, with expenditures manufacturing full-year and to the to deliver in an margin our over in as to higher is the resulting and our revenue in invest to in We operating to

the are half execution our successful we of team's of up, first proud the in of we strategy wrap XXXX. and the delivered performance To

remain revenue, of margin in $X Looking ahead we in billion XX% gross the to confident mid-teens. and XXXX, margin our operating targets of in

have to to and positioned value We well these is the Insulet deliver and momentum sustainable strategy achieve right growth and goals long-term, creation.

I'll to now Shacey remarks. turn call back for concluding the her

Shacey Petrovic

Insulet. Thanks, am excited Wade. I for the speak entire the on opportunities behalf I team ahead I say when that of about

out-performance half strategy first creation. financial of are and value track record the our a in great position of our of ensure Our shareholder continued continue XXXX in to strong we execution proven

call I Q&A. the would operator back turn Now, for like to the to

Operator

[Operator you. Johnson our from with Baird. question first And Instructions] comes Jeff Thank

Your line is open.

Jeff Johnson

Good on quarter back Thank Congratulations guess. and you, afternoon. the the I guys, news quarter

Shacey of TX? questions bit in any DASH, change a pharmacy easier the mix here, on two TX Obviously change on one channel are the any little so seeing there any competitive MDI mix So coverage just with get patients to you quarter, increased versus or through wins the a conversions?

Shacey Petrovic

I Jeff. question, it's great Yes, think a

So pretty MDI versus from steady. X the wins competitive pumps rate of

XX% still started is coming while could some So have in tight is X of turn I mix the indications approximately on injections DASH. of to new into we multiple our patients patient think trend our exciting daily an new see early what from starts

messaging trend population resonate really we we see have think tick is and encouraged focus started to that starting our there So and are I to up and our call it's to a users. with it on physicians a too but early that with

Jeff Johnson

line can of your right service to you some maybe start-up initially US we months a costs just in that? of anything the Wayde in demand of think that's out And consider or make I confirm too would All manufacturing I the facility little how question don't of Thank your to higher bit then much there's the over issues you read ramp-up sure next than in expected say the the costs months to pretty XX kind percentage to thinking. are I you comments you, don't to where or maybe you. on and want with a see just tariff , are manufacturing X but were for helpful US any what much right lines manufacturing but between want

Wayde McMillan

You bet. Hi Jeff.

So, with regarding are right our they manufacturing line in costs, expectations.

gross the for margin our of changed not have guidance since beginning the We year.

And so it I is, would right. very in line, much say makes lumpy, it what

and for manage we in have the our we deal of to lots volume up with. between lot China we have we work that manufacturing through through of As a legacy US our ramp scenarios so plant new as here and running and volume our

We have it's higher to as small very the amount a more a inventory we is expenses overhead ramp in cost. product then period put absorbing volume so we and beginning, cost and costs, higher at US start period at in of up in because across lot inventory manufacturing initially a more the small made a

So going and expectations that. in work to years. going line be right a It's through team our to having it's been lumpy the to with that we're several said this working on but take while for us has

part strategy the our redundancy It's from it. big we of a get ,

term out also get of We long efficiency it.

the term to that the and work to something of working strategic just we're day the right it's move. at it's so have end financials the And but medium here through the through going in

to of I we're of to out here to it's at months, question, done job all team and demand, was XX has to US will the great round US impact what tariffs I tariff regarding a last everybody it third And team into than will and we for of details why that's get that. latest job mitigating mitigating is date, scale And waiting it a immaterial it this our doing caught think on come if then to the full then and longer the the line, still not and XXXX. nice the real that those take We'll next and be have exactly think to part I regarding like point calling mean the in won't date. get we're in second but the X demand tariffs

And as in manufacturing driven turns and team serve for then tariffs strategy although from an capacity out but it get the facility, here by won't the US of obviously able and was US we the increased US our for it not issue to scale the do the to will part a manufacturing US once we , all. at be be redundancy

So, very strategy our is with happy long-term manufacturing how coming together.

Operator

you. Thank

from comes David your Stanley, Lewis Our is next Morgan with open. question line

David Lewis

start where and on afternoon the clearly inflection quarter Shacey going to Good it. to be and focused people an are inflection wanted US obviously with, and is congrats, I

you So business details Shacey, I wonder, to this just for you give your historically but us yet move hard more quickly it. it's did

when DASH, lowering access, is Is particular greater this I it think about the question for to on It it because pharmacies just a of So you quick access US, payer in just getting enthusiasm that the Wayde. the access drivers, quarter around system? helpful, have the be would

Shacey Petrovic

Thanks to David. for really pharmacy And more to you really, and I pharmacy rationale highlight as all and helping be go, the it for attractive adoption. lower customer is better experience, a then barriers our with you it experience that us customer was combined would be over strategic channel the it a pay the could would time, is the improve above. of

the starting patient our And access users years, complexion so more appealing this physicians is increased not about to that's might and a that a idea more have for earlier to that it starting I X to and patients see product little just to four change that of expand in patient having for the an think aid physicians and see subset now Medicare really and of so prescribe I are color we're done so that much bit about of Omnipod users patient product base, you worry think population. patients clearly what prescribe thinking more you're terms patients maybe certainly for to DASH in the to can is a visibility for both for otherwise and seeing a without but type way helping a physicians helping there user walking that also is that

is really growth. the platform, and Medicare the installed base it helping strength the then Medicaid in increased the really pharmacy record that of access strength in and starts drive combine So model, business new pay-as-you-go to business both the in product and patient model the

David Lewis

which helpful just Okay, and just this Shacey ex-US Wayde gross the --can we you third us apples the the so apples quarter give much. quarter and ex-US inventory to of really and Nice half first we second into very comparisons mindful how quarter any underlying Thanks growth which growth up is should apples-to-apples be for indirect as basis. about thinking an head adjusted you quarter. on

Wayde McMillan

You David. Hi bet.

to guidance So process the our had and the decline QX direct had in growth and big moving boil some through QX sequential from distributor one is the the it as rate into and XX% note, in or the where Europe also QX down were on pieces, year two a tougher increase positive converting through inventory to easy year. basically as last process challenge to our that price we last in for this biggest QX which there around year direct impact disruption is going an for we become buyback work comp comps out then well

performance can So David, about about XXX% down normalizing together to all that half. a the guidance working when it, you from so QX, we've anchoring than QX to at if that we're that you really had you other really end, for to about over impact, put XX% range high look XX% XXX% that the our to think the just the it's international first at and transition

pretty so and And US growth. And O-US that's across strong regions. really both

we've are QX, a think actually normalized on for I about just add higher basis. And than I then a would we little talked

we've we several the for good and teens, into above guidance here this reasons high a increase. times low-XXs So, the normalized in couple small we've And visibility that is there's quarter and look that it slight Europe is that internationally a then at and international the there growth our looking hangover in guidance said gives were again pipeline the think of in got last strong. year us from disruption a QX rate

the or to of here to And the small to in that's and year easy slightly comp our took XX% we and so pipeline us what compared of QX. The strength a momentum. XX% QX impact gets last

Operator

you. Thank

Our next JPMorgan. Robbie question comes from with Marcus

is line open. Your

Robbie Marcus

kind David patient was Thanks international on quarter. the we're was that my there US think nice said price that you out patients and for second the increases we're you we the do of What that similar just maybe you seeing, price then if quarter. understand you help Wayde, a all question about for And of that asked question on for but taking the could us do congrats really a the that DASH getting good the portion higher in a underlying think volume in quarter? XXXX?, how strip

Wayde McMillan

question. Rob, there? still you still there? Rob, your of We might have lost end just you the

Operator

just lose Robbie It we the apologize. line do Marcus. did of looks I like

Wayde McMillan

Okay,

Operator

to on the go next next our will We question, question...

Wayde McMillan

then comes know that, we'll please Robbie and do then to get we queue, question. back his don't when us in Why -- let

Operator

with we'll sir, next take question Yes, the Wuensch until then, BMO Perfect. Capital Joanne Markets. from

is open. line Your

Joanne Wuensch

it launch and trials we one shortly and how are for clinical the everybody. afternoon, of questions, the trials is to we do like the then Horizon full still starting about talking end sounds track on steps Two get launch? next the year, to Good from first clinical it's

Shacey Petrovic

we're in Yes, focused we've we I and Joanne. Horizon said excited three Thanks areas. with think are as

transition is, we're first have injection we're can the we from third and on was on about the going ensuring ease that we presented focused is just -- at which market multiple daily were is, users the EDA. phone research on to perspective to, that we indicates then that a our So, control focused system data with really development be all a are why is the And a of game changer users. launching pediatric which use indication so for excited the focused

of have the a an flat the for that hopeful system accelerated we're release into that to that FDA the complete to those the either move that is between pivotal benefit or leverage outcomes that and with believe product then and into release designation able we'll work we pivotal and we going limited commercial as market to and achieve the because commercial then we're system. be development to of we'll protracted the to breakthrough are the looking market release So somewhat a and review entered from that full market with now limited devices of enter pivotal and

market So in our is the year. next of half to second goal be on the

Joanne Wuensch

want a you. revenue your small or there business? call the Thank a bit to of question, you but normal or just then, way better less little I a such this did is is of just to then and at, look out And delivery I something think there course with drug ask percentage worse, about

Shacey Petrovic

It's is forecast of from always performance Our our largest business, for delivery the guidance based normal and primarily on for course customers. drug

So what and standpoint. from a performance guidance both reflects that that's

Operator

Thank the you. has rejoined Robbie queue. And Marcus

from Our next him, Marcus, Morgan. Robbie come question does JP

Your line is open.

Robbie Marcus

upgraded the second substantial PDM your be know we need a there underlying that a much what at Thank in it that just appears I that the asked little to international volumes get better. but heard know the portion Wayde, David comes but like DASH don't of will higher that you price growth, DASH without underlying didn't was of hopefully on time kind just, a how I you, and to I base a ask, PDM. wanted

how it's XX XXXX? I us about pure that and understand was? help just growth Can this the this 'XX, year underlying just ' US metric And patient in for for year. So what you the help know volume think understand did installed year. growth us to price increase you

Wayde McMillan

Robbie have glad bet back. Yes, to you you

a reminder mentioned So customer price we the product, the increase of don't pharmacy DASH starts that to time for some than benefit you a are not existing as so what customers significantly different experienced and for give the a on overall are we from PDM. a who mix them but are we for have patient It's getting move growth first and coming new people where the is channel on isn't premium into and new DASH, there another and

not a you material for all was as our believe and as on quarter benefit well when the a slight it unfavorable headwind so, that net impact really results. out, we our the a And just PDM from that

in people netting mix So the benefit headwind the the moving in DASH pharmacy. and PDM with the on of

or can think new our plus significantly onto of on didn't benefit have different they're customer previously from another product we people those. moving overall So on DASH rate I patients not that our growth have don't So not because increase price think or mix as you growth a about the premium we moving from

Robbie Marcus

on I guidance the are lost a each quarter. commented stocking pharmacy, the is there second like about at you've PDM think the and of from the have I if to balance does DASH don't then decelerating the year, and trends price if benefit offsetting guidance seems it if and any I for when look the degree, to the credit of from it balance headwind of it in year other know Great appear the

to the understand just patient a So, reflective a in Thanks second underlying quarter, volume growth New each benefit results? don't the help us growth what you lot. is pretty quarter have help gets the understand starts us if of slower second individual half. huge in

Wayde McMillan

Sure. bet. if me there I any Well, know a is let of so Yes, through lot worked Robbie it. it, miss there you

regarding PDM, QX talked had So the we the to a rata, QX. We've over about pro amount three quarters, a rata pro

XXXX had net start we for still net I neutral. QX, in mentioned, QX that we and the that XXXX be then in offset slight across a so pharmacy to we for assuming the in accrue XXXX, and DASH PDM as As same a assumes more basis that fully we're unfavorable a on the for patients on planning we're neutral here will

if growth XX% the in the had rate first that's So US we've the for rate from a end look growth at QX, same our half. of guidance high you as standpoint,

up like year our and XXXX end at the doing very of about we're the we're it last we'll did we lower more end accelerating we way guidance we seen we've which that well, is up if thinking in growing acceleration up the half range. more still If with the in continue our of end high first end So will guidance. at like end the

how its it's half XXXX the here at the really we spectrum, in accelerating end through of thinking XXXX just and strong first believe we've we're about growth. So how been of either accelerating and

then of things teams our working quarter happen well product an just lot that US years but capabilities US, doing lot here into said in we're incredible talks just obviously our job have with as has helping managing a and capabilities them seeing as make and of run. working build and Shacey we that the to the here teams past business had US sharing US also up a about well, Having new and months one the few in shift pulled through. making, for and in manufacturing ramp getting we all a model they're the manufacturing launch and our are new a all that they're our European to doing and through patients

So expectations things very time and the the we during how just and an work QX. same team of at through here happening it our of exceeded proud amount incredible and actually

of US the us gives realistic high end what that but also range being still a did XXXX. all the year the above we that in in if we what we through up XX% the can that's So things. we're will just of at last that hit lot confidence working of be at low end end And frankly,

Robbie Marcus

quarter. and again Thanks nice

Operator

Thank you.

Our with SVB Antalffy next question from Leerink. comes Danielle

Your is open. line

Danielle Antalffy

taking for Congrats afternoon so guys. Thanks a good the Hey, quarter. great question. on really much

that already think and customer on about or Have going you up about move talk time guess. I Just -- a of from has follow can follow-up with better and question maybe as go some to there through an Shacey, DASH the attrition pharmacy? the perspective? start DASH around meant commentary with where etc., the your also what you over what mean sense that ultimately could you we you do can seen have that to think needle experience

Shacey Petrovic

we've actually of that customer it's able no question up the going predicted be the with see rate. we'd the were get to grow a that There higher. us slightly base Danielle, evidence ultimately product is analysis We to right On I customer monitoring up. think it's closely. a our was attrition because great the and that at we attrition to higher Higher decision we we tick attrition grow balance, that a to been rate something barriers was quarter base this end and even rate, lower if all demonstrate could onto the as that we

expectation so was. product we're business model, the both appealing seeing would accelerated that model differentiated customer and the , how business And in our indications that also the was is way an but just what grow base early because DASH the how of

business are about model were So we good that indications attractiveness. our right I think the early

going we're watching carefully. the think very attrition to I rate, be

get Just barriers to tuned product, the color see we what get these We'll happens as stay onto we on provide lower as front. it. to that so certainly

Danielle Antalffy

one Okay quick follow-up. one's for and just probably, you. this Wayde then

manufacturing all You have maybe perspective, in at transitioning and lots from here on headwind were constraint better? that actually quarter any did a guys a supply have of that sales? done could impact the you Was

Wayde McMillan

we're shape No, supply Danielle. of Hi, here. plan really the standpoint from and in redundancy good part that's a

to sure launch, heading heading ahead just we we're built fact manufacturing up and act we it. into In into the DASH and inventory of ramp make the some inventory built

a very feeling and about good manufacturing in we're standpoint. So we're situation from supply the

Operator

Thank you.

from Our Matt UBS. Taylor with next comes question

is line Your open.

Matt Taylor

you question. thank for Hi, taking the

don't one to are when the I that think ask the your you the wanted or horizon. combination other still ace sure with about Can just late to systems know wanted future you drive So to said make systems. if combination sensors that talk with in you I about just about And question targeting other plans ability you designation? today. to XX, I have

Shacey Petrovic

Thanks, be Yes, to next to we the we're end of the market in still did confirm I second in at pivotal and this the year. year that Sure. and half on track plan Matt. of

it's behind And system tight the one other to progress. that be with rationales we expect very system algorithms with our pool a etc. so work I'm partnering do that that of can excited have about other fully We inter-operable sensors, and

see horizon interoperability planning is Dexcom we at our is the value and the about are the and Partnership terrific control. very value So, that point, for in partner but road firm the which are down we sensor, of excited their Dexcom this and with

Matt Taylor

you've trends More for seeing come too. the accelerating Can could had the the strong over that the broadly, market trends, growth Thank as what and new out? clearly couple these we're sustained you you. you in talk talking about the that talk Could competitor about the your here next about of is market. years how underlying very just you think growth be technologies pump was

Shacey Petrovic

Sure.

us in years last Matt, trends, and patients that. as of to know look CGM and they we the adoption what get few accelerating and that's terrific the is because they their glucose is piece get always part market due happens better has grown say obviously that pulp for growing You in to tighter are control accelerated there for is opportunities the that CGM to control been has it then tools better visibility Omnipod recognize a of and get big to

address go the to does majority of helping helped So the of helped has injections, because big thing one of patients certainly in has that's the is and the are adoption pump market vast that to our CGM Omnipod grow multiple with category. that been comfortable to so Omnipod growth of the particular that's a wearable growth other increasing the adoption hurdles of of to overall the has fuel CGM part get CGM too patient overall daily and a we're so and from course coming a

United market States X% that We a in growing markets more United than less of XX% mature States itself are XX%. that compete somewhere somewhere it's and is believe and that markets, around in, these outside somewhere between we which growing the the the primarily in CAGR European the

getting a we're nice share of a overall bigger obviously so market. that and growth And

Operator

Thank you.

with Kaczor Blair. comes question William next Our Margaret from

open. is line Your

Margaret Kaczor

the taking afternoon, questions. everyone. for Thanks Good

as for DASH First for , XX% was on the the helpful. gains all Maybe those you on at the call, you have guys the front that follow-up guys off of now. helpful coverage some just new thank metrics on a from

pharmacy patients of is to Type are all on numbers think today? And inclusive we pharmacy mix then XX% we of shouldn't what to assume up start higher, see benefit, it and XX% about if these of benefit you're under the picking I X see that why continue you that we referenced, as patients? kind that should

Shacey Petrovic

It's and the under through the vast a DASH today of has is But Margaret. DME Thanks, both pharmacy the covered coverage pharmacy. majority

about past patient. for Type the reduced in in spoken the pharmacy the for we've particularly adoption obviously So barriers the X

that for have in for we true the DASH established that's majority the so of And the coverage users vast pharmacy.

we to In the of establishment with adoption, we see already, as base starts and going. adoption ramped move quarter patient of accelerate that will that takes kind to earlier, but access terms DASH the expect and we're of a acceleration overall obviously needle third the mentioned so on early where Robbie in started for new being of adoption indication of it our indicator long quarter the that's starts already commensurate us of think would time patient I a an where is DASH in new indications of but an seeing the landed access we throughout I

that's are So strong. early indications exciting very think the perspective, our I from

Margaret Kaczor

this quarter year kind happened then just control one into and Thanks. channel and maybe again base or Okay. a And this and notable that yourself the that update year. was going question X channel, mix of of any maybe why Type kind understanding there of that of into And either guys any maybe the part more get revenue second kind that see of you next shouldn't side, from going some with we maybe direct into moving your the the to forward. patient continue going because coverage model, as that benefit, on installed of existing of changes having half

Shacey Petrovic

we why that with great for in would the to as but pharmacy which the And as X to thing tailwind us it is the had continue that remarks access same to X that living is channel people a the grow patient the that we population that think my more part opening access the physician, a for shared and to type we forward dependent continue etc. grow I was establish of the expect in diabetes for Type was Yes, Omnipod. this into as for through is we rationale I of insulin channel expect true see to transition we pharmacy that strategic attractive for in rest going that year

there grow as establish we access as to And population so we more do well. expect that

Operator

you. Thank

comes from Our with Raymond next Jayson question James. Bedford

Your is open. line

Jayson Bedford

Hi, good afternoon.

Is quickies prescriber here. source to way that about quantify number if there seeing? of is of new indeed an base you're of Just wanted US I a you a the on prescribers faster meaning ask can the growth. comment or the any expansion couple growth

Shacey Petrovic

Thanks, Jason.

in as haven't that new penetration the significantly. We into our we I well shared both existing prescribers track say new will past. clinics or of increasing as and both are clinics

term I are more the we're board. store new put both getting, it same-store guess colloquial to getting across in we So a sales more more sales and

Jayson Bedford

expect to file when then, designation? And for do Okay. ace you

Shacey Petrovic

We haven't shared that.

for We it's have additional have really said advantage that but necessary we pathway, we of fully expect not us, to until that sensors. take

You know that ICGMs. our

a in likely not but part we're both and So hurry is Horizon. at it our of Tidepooll strategy for

Operator

with from our And Cowen question Ryan you. next Company. and Blicker is Thank

open. Your is line

Ryan Blicker

base do range you XXXX and guess the afternoon my And Maybe at previously? just I that good for now half growth, to you in guidance, it base is be base with similar international, international mentioned installed per consistent still starting growth? expect revenue with for in question taking still 'XXs you that in to the Hi, least growth questions. installed the US or year the second grow expect do higher given low thanks installed

Wayde McMillan

Sure. Yes.

Wayde, is can this So Ryan. I serve

think about DASH DASH product increase who a not in from anything. the a of are is before, to pricing new not people I but people on because DASH for not they're we're change that new are they're number price tough now similar is a the to that clarification installed little point, base a it but we and overall sales this growing deviation bit don't right bit assuming significant it's the to at a bounces just and one are see in lot moving and a there to We growth rate a think around because of it's gauge

an increase think model So it's not is although selling 'XXs we DASH growth to high-teens-low pay-as-you-go price overall are From an uplift it's we with price going rate. base customer that grow -- a the that standpoint, getting in premium our to because it's us. pod but international average in been for primarily for the the should also

the driver primary is region. our so And the in that's growth expectation for

Ryan Blicker

Great.

international, of to you've incremental think growth basically teens off talked low about, that major starting you about markets think to in should significant new Okay. just like with be only 'XXs you. incremental it maybe And be new doesn't XXXX, sound sticking could market that will that some XXXX. that we slight of should it Thank it is we about any talked or how then, high a expansion but benefit

Shacey Petrovic

the Thanks, Ryan. I business us, term. the about for long model is Yes, think all

it's going in base term. a to and business retaining that the market one really any that building year be So isn't over customer about at all, long major and given all contributor any

long-term I So contribute thoughtful to all be how we that a of contributor story really number it wouldn't significant at that. be It's expect can want a years. to the and in XXXX. really about over about

Operator

you. Thank

Our next your with line Berenberg is question comes from open. Misra Capital, Ravi

Ravi Misra

Hi, great, okay? thank you. Can hear me you

Shacey Petrovic

Yes.

Ravi Misra

or questions. question the taking a for Shacey, then thanks one on Great, just Wayde. Type had X and I follow-up

you're Type on strategy into patients as does these you your patterns just that working same the So help of that the Systems have it think X how the mentioned, more reorder some on? seems with kind Type and us fit do can you Insulin commentary success, of early Delivery concentrated this about X

Shacey Petrovic

Yes, I great question. a think it's

type versus but differ patient insulin early So really is X. there type again that utilization X it's indication the no patterns really or days. with dependent reorder

new strength in patient patient indications starting just we're of this starts. in see to So our population

a reorder gather we larger that patterns about time, in As utilization and more we'll base and over base. learn retention

relates it making great our As there. concentrated progress to insulins,

either I of a to have in we the U-XXX submitted think a that to never or it's call we And major have never, has to niche revenue, mentioned last more the really that we had ADA FDA. that intended product. contribution

U-XXX discretion early type about but see research helpful not required DASH insulin will year potential with this with insulin significant experience to but certainly we population insulins standpoint, saying to probably and and dependent in appealing in has patient have come X technology we're the showing ability simplicity reduce us type and dependent and have effort a concentrate and in a with from that fact insulin to now majority that population, more the both for to access of be product market people for today with to making also concentrated not total is been and the patient Xs of dose market. definitely the an demonstrate probably we at now the that of growth Omnipod's wait daily living insulin's is value how this

Ravi Misra

then curious Wayde, one maybe you, you vanquish, kind it's just a accounting bit give but or for that Great, as thanks. just of that And phase just the through little or out. away flow PDM

associated that that with kind how year margin Thanks. your is gross curious, targets that approaching and or the about warranty we upside? that around incremental XX% three should Just of built expense into think is

Wayde McMillan

is assume we depending built and in It level. on would the experience

of goods experience and levels it what our still accrual our materially wouldn't and a but as we're result warranty to at on unless product change upside product, benefit changes as see the new or days as change that. then early experience accrue cost the the we the don't issuing .So that a So warranty warranty we we because on we change the our our it's product factor new that's sold see of

updated an don't we have estimate. So

Operator

you. Thank

Kalia with Our next question comes Northland. from Suraj

open. Your is line

Suraj Kalia

of the level, in was Shacey, taking nice let of we that, ADA questions for congrats systems all data competitive at the any Good XX have for TIR seems think afternoon, out my trying at to the the guys everyone. you that advantage Thanks with XX, and kind and one on a ballpark. understand me fundamental rendered closed-loop control with to things start be of IQ Medtronic on preliminary least I quarter.

from Because the did in to be free the headed would is of architecture of lack it was love system of a you I'd improvement? I CGM? I'm terms to it this breaking to about algorithm? do relative a it guess key raised is mentioned get thing think remaining? you where Is one and think the last at is year's Omnipod, that somewhere clustering disconnect your ATTP get There the pump? love Shacey, needs the thoughts, your you what and Or the advantages, also seems I thoughts, the

Shacey Petrovic

for is the I say average is range children, Thanks very a and with would in Suraj. time from living that's think time The time that Type X maybe range person in population the in XX% ages XX% a 'XXs, which question, range. I average X remarkable challenging today. very, sitting improvement to diabetes X and especially

difference algorithms marked are great a of sensors the and and increase it automated that a quality life. the insulin and and pumps So of this will community in to outcomes make great is delivery addition and of bringing terms

the just we user think are of one that's come down of what's so we all great and more of the and I going of convenience trials more use on help but how to control, can focus systems which these to think would system great is in outcomes about When actually use. easy are a and use on drive systems phone because ease life well-controlled deliver world of reasons ease great deliver on why of more outcomes use breakthrough adherents these actually to and in much ease it real going quality MDI the clinical to

breakthrough differentiation we that's words. we where of So your use can where kind focused think to and get we and really

Suraj Kalia

number of of Got had of patients adds it. a third X's. a third new heard Shacey, patient correct finally, me T terms versus of comments the were in if TXs. it, misheard a of the starts work out Can And patient patients made were DASH a was I and thing number your I parse a of DASH, new and TX's please you what other know percent I the

some see the arms love great just of the guys, summer level Tandem taking have you you parse give know, the know and you T to on X's obviously TXS. X's I'd we within for around we questions for trying numbers Medtronic, especially quarter. our and of penetration congrats guys idea put US. guess T current I Thank a my and to out but in penetration I of TXs

Shacey Petrovic

Yes, that all-time was high Suraj. but just that as don't in I a starts. new an mentioned out, we this break terms Thanks, I of patient record say -- will for us

indicator dependent significantly we're across the leading TX And everybody. If both notable an Type we and Xs a picked to turns population new in going users Type trend. insulin which was tell DASH great is that had in up so did X interesting it adoption have into that and

Operator

at remarks. I over showing now to And I'm any for you. would the not further this any time. like questions Shacey Thank call Petrovic further Ms. turn to back

Shacey Petrovic

on us call. everyone you for Thank thanks joining today's and

a impacted all your evening. improve you dedication hard work our and the of and momentum delivered diabetes. without by months Company to updating None would and half of a to the world and of team to lives strong continued day you this in out the I living to second positive year have finish. than just from now half With and that, the Insulet look for diabetes. building expected the great day results are start with people of XXXX progress forward of the us be a We progress better ahead. in possible to all stronger great Thanks in Thank all around who on and tremendous first our expect works

Operator

participating gentlemen, and conference. in you all Ladies wonderful a disconnect. have does you conclude This and today's day. thank Everyone may today's for program

Insulet (PODD) 5 Aug 192019 Q2 Earnings call transcript